Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M.

Lancet. 2004 Dec 4-10;364(9450):2021-9.

PMID:
15582059
2.

Rofecoxib for rheumatoid arthritis.

Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Wells G, Tugwell P.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003685. Review.

PMID:
15674912
3.

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

Weir MR, Sperling RS, Reicin A, Gertz BJ.

Am Heart J. 2003 Oct;146(4):591-604. Review.

PMID:
14564311
4.

Rofecoxib for osteoarthritis.

Garner SE, Fidan DD, Frankish R, Maxwell L.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD005115. Review.

PMID:
15654705
5.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246
6.

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.

Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.

Clin Ther. 2005 Aug;27(8):1196-214. Review.

PMID:
16199245
7.

Risk of cardiovascular events associated with selective COX-2 inhibitors.

Mukherjee D, Nissen SE, Topol EJ.

JAMA. 2001 Aug 22-29;286(8):954-9. Review.

PMID:
11509060
8.

Rofecoxib for the treatment of rheumatoid arthritis.

Garner S, Fidan D, Frankish R, Judd M, Towheed T, Wells G, Tugwell P.

Cochrane Database Syst Rev. 2002;(3):CD003685. Review. Update in: Cochrane Database Syst Rev. 2005;(1):CD003685.

PMID:
12137705
9.

Rofecoxib for the treatment of rheumatoid arthritis.

Garner S, Fidan D, Frankish R, Judd M, Towheed T, Wells G, Tugwell P.

Cochrane Database Syst Rev. 2002;(2):CD003685. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD003685.

PMID:
12076502
10.
11.
13.

Single dose oral rofecoxib for postoperative pain.

Barden J, Edwards J, Moore RA, McQuay HJ.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004604. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004604.

PMID:
15674955
14.

[What do we know about the cardiovascular toxicity of the NSAIDs?].

Sibilia J, Deray G, Montalescot G.

Presse Med. 2006 Sep;35(9 Spec No 1):1S11-23. Review. French.

PMID:
17078591
15.

Current perspective on the cardiovascular effects of coxibs.

Konstam MA, Weir MR.

Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. Review.

PMID:
12086293
16.

[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].

Valat JP, Deray G, Héloire F.

Presse Med. 2006 Sep;35(9 Spec No 1):1S25-34. Review. French.

PMID:
17078592
17.

[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].

Valat JP, Deray G, Héloire F.

Presse Med. 2006 Sep;35 Suppl 1:25-34. Review. French.

PMID:
17870550
18.

Are rofecoxib and celecoxib safer NSAIDS?

[No authors listed]

Drug Ther Bull. 2000 Nov;38(11):81-6. Review.

PMID:
11138599
19.

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

Ann Intern Med. 2003 May 20;138(10):795-806. Review.

PMID:
12755551
20.

Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.

Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE.

Clin Ther. 2001 Jul;23(7):1061-79. Review.

PMID:
11519771
Items per page

Supplemental Content

Write to the Help Desk